Horizon Pharma Bets On The Luck Of The Irish With Vidara Buyout
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma agreed to buy Ireland-based Vidara Therapeutics in a cash-and-stock transaction valued at $660 million. Horizon will gain a new commercial product, Actimmune, to add to its portfolio.